CytoDyn Inc. (CYDY) stock
CYDYOTCPharmaceutical PreparationsFiscal year ends May 31
$0.25+0.02 (+9.53%)
Close on Oct 19, 2026Market cap $345.56MP/E –Yield –
CytoDyn free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
CytoDyn's free cash flow for the twelve months ending Feb 28, 2022 was -$104.54M. For fiscal 2021 it was -$117.70M. The highest annual figure on record is -$1.83M in fiscal 2011.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | May 31, 2021 | -$117.70M | – |
| FY2020 | May 31, 2020 | -$68.85M | – |
| FY2019 | May 31, 2019 | -$50.49M | – |
| FY2018 | May 31, 2018 | -$29.90M | – |
| FY2017 | May 31, 2017 | -$26.74M | – |
| FY2016 | May 31, 2016 | -$24.82M | – |
| FY2015 | May 31, 2015 | -$12.04M | – |
| FY2014 | May 31, 2014 | -$7.41M | – |
| FY2013 | May 31, 2013 | -$3.40M | – |
| FY2011 | May 31, 2011 | -$1.83M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$11.06M | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$28.90M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$31.75M | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$32.83M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$23.67M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$20.19M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$41.01M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$29.32M | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$17.54M | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$6.79M | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$15.20M | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$9.54M | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$14.76M | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$17.22M | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$8.97M | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$6.98M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$7.17M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$8.80M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$4.51M | – |
| Q1 FY2017CQ3 2016 | Aug 31, 2016 | -$6.26M | – |
See a number that looks wrong?